Clinicopathologic differences among patients with behavioral variant frontotemporal dementia
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To characterize the presenting symptoms and signs of patients clinically diagnosed with behavioral variant frontotemporal dementia (bvFTD) and who had different neuropathologic findings on autopsy.
Methods: This study reviewed all patients entered as clinical bvFTD in the National Alzheimer's Coordinating Center's database and who had both clinical and neuropathologic data from 2005 to 2011. Among the 107 patients identified, 95 had unambiguous pathologic findings, including 74 with frontotemporal lobar degeneration (bvFTD-FTLD) and 21 with Alzheimer disease (bvFTD-AD). The patients with bvFTD-FTLD were further subdivided into τ-positive (n = 23) or τ-negative (n = 51) histopathology subgroups. Presenting clinical signs and symptoms were compared between these neuropathologic groups.
Results: The patients with bvFTD-FTLD were significantly more likely than patients with bvFTD-AD to have initially predominant personality changes and poor judgment/decision-making. In contrast, patients with bvFTD-AD were more likely than patients with bvFTD-FTLD to have memory difficulty and delusions/hallucinations and agitation. Within the bvFTD-FTLD group, the τ-positive subgroup had more patients with initial behavioral problems and personality change than the τ-negative subgroup, who, in turn, had more patients with initial cognitive impairment and speech problems.
Conclusion: During life, patients with AD pathology may be misdiagnosed with bvFTD if they have an early age at onset and prominent neuropsychiatric features despite having greater memory difficulties and more intact personality and executive functions than patients with bvFTD-FTLD. Among those with FTLD pathology, patients with τ-positive bvFTD were likely to present with behavior/personality changes. These findings offer clues for antemortem recognition of neuropathologic subtypes of bvFTD.
Glossary
- AD=
- Alzheimer disease;
- ADC=
- Alzheimer Disease Centers;
- bvFTD=
- behavioral variant frontotemporal dementia;
- CBD=
- corticobasal degeneration;
- FTLD=
- frontotemporal lobar degeneration;
- FUS=
- fused in sarcoma;
- MMSE=
- Mini-Mental State Examination;
- NACC=
- National Alzheimer's Coordinating Center;
- NIA=
- National Institute of Aging;
- NPI-Q=
- Neuropsychiatric Inventory–Questionnaire;
- PSP=
- progressive supranuclear palsy;
- TDP-43=
- τ or transactive response DNA-binding protein of 43 kD;
- UDS=
- Uniform Data Set;
- UPDRS=
- Unified Parkinson's Disease Rating Scale
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The byline for this article was updated on June 27, 2023.
Supplemental data at www.neurology.org
- Received August 20, 2012.
- Accepted in final form October 4, 2012.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Re:Episodic memory - a good diagnostic predictor to distinguish pathologically confirmed bvFTD and AD?
- Mario F. Mendez, Neurology, UCLAmmendez@ucla.edu
- Los Angeles
Submitted March 14, 2013 - Episodic memory - a good diagnostic predictor to distinguish pathologically confirmed bvFTD and AD?
- Michael Hornberger, Neuroscience Research Australiam.hornberger@neura.edu.au
Submitted March 07, 2013
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Age-at-Onset and APOE-Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer DiseaseDenis S. Smirnov, Douglas Galasko, Annie Hiniker et al.Neurology, March 15, 2021 -
Article
Clinician-judged hearing impairment and associations with neuropathologic burdenWilla D. Brenowitz, Lilah M. Besser, Walter A. Kukull et al.Neurology, August 05, 2020 -
Article
Comparison of symptomatic and asymptomatic persons with primary age-related tauopathyLilah M. Besser, John F. Crary, Charles Mock et al.Neurology, September 15, 2017 -
Article
Cognitive heterogeneity in probable Alzheimer diseaseClinical and neuropathologic featuresYuqi Qiu, Diane M. Jacobs, Karen Messer et al.Neurology, July 18, 2019